• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22336 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     NIHR Health Technology Assessment programme A pragmatic randomised controlled trial and economic evaluation of family therapy vs. treatment as usual for young people seen after second or subsequent episodes of self-harm: the Self-Harm Intervention - Family Therapy (SHIFT) trial
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Promoting mental well-being in children and adolescents]
2022     Penn Medicine Center for Evidence-based Practice (CEP) Patient bias against healthcare providers
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Transient elastography in non-alcoholic fatty liver disease]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Stem cell therapy in selected orthopedic conditions]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Dapagliflozin for chronic kidney disease
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Biofeedback in adults with urinary and/or fecal incontinence]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Systemic thrombolysis by alteplase for acute ischemic stroke
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Electrosurgical units in surgery]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Systemic thrombolysis and endovascular therapy for large vessel occlusion acute ischemic stroke
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Psychological Treatment for Postpartum Depression]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Swallowable gastric balloon in obesity]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [OncotypeDX in breast cancer]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Vistaseal™ – Intraoperative bleeding]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Coronary intravascular lithotripsy in coronary artery disease]
2022     NIHR Health Technology Assessment programme Plasma exchange and glucocorticoids in anti-neutrophil cytoplasm antibody associated systemic vasculitis: a randomized controlled trial. PEXIVAS
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: perineal and pelvic rehabilitation for the prevention and treatment of pelvic floor dysfunctions – Part 1: Urinary incontinence]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Intensity-modulated radiotherapy for prostate cancer]
2022     Health Information and Quality Authority (HIQA) Catalogue of institutions undertaking COVID-19 horizon scanning
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Optical coherence tomography angiography in vascular eye diseases]
2022     Institute for Clinical and Economic Review (ICER) Medications for obesity management: effectiveness and value
2022     Health Information and Quality Authority (HIQA) Planned public health measures and strategies to limit the impact of COVID-19 surges: an international review
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Ultrasound therapy for scar tissue]
2022     Institute for Clinical and Economic Review (ICER) AMX0035 and oral edaravone for amyotrophic lateral sclerosis
2022     National Institute for Health and Care Excellence (NICE) Cabotegravir with rilpivirine for treating HIV-1. NICE technology appraisal guidance 757
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Advanced lymphoedema: can non-medicinal procedures relieve symptoms?]
2022     NIHR Health Technology Assessment programme Randomised control trial of surveillance and no surveillance for patients with Barrett's oesophagus - BOSS (Barrett's Oesophagus Surveillance Study)
2022     Ontario Health First trimester screening for risk of preeclampsia using a multiple marker algorithm
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: pharmacotherapy in the treatment of obesity]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Diamine oxidase activity test for histamine intolerance]
2022     Institute for Clinical and Economic Review (ICER) Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects [updated Sept 29, 2023]
2022     National Institute for Health and Care Excellence (NICE) Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy. NICE technology appraisal guidance 758
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of immunoglobulin in fertility, cardiology and other indications]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for head and neck cancer]
2022     National Institute for Health and Care Excellence (NICE) Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 760
2022     Andalusian Health Technology Assessment Area (AETSA) Electro-hipertermia modulada en pacientes con cáncer de páncreas, cáncer colorrectal avanzado y gliomas malignos
2022     NIHR Health Technology Assessment programme Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Phakic intraocular lenses for high-grade myopia]
2022     National Institute for Health and Care Excellence (NICE) Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. NICE technology appraisal guidance 761
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Depression in children and adolescents: does psychotherapy lead to better results compared to other therapies?]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Portable home hemodialysis systems]
2022     Center for Drug Evaluation (CDE) First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Eye controlled speech generating devices]
2022     National Institute for Health and Care Excellence (NICE) Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal). NICE technology appraisal guidance 762
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cystitis: do herbal remedies help with recurring, uncomplicated cystitis?]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: solid organ transplantation – Section 1 - overview of heart and lung transplantation in Québec]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous coronary interventions (PCI) for chronic total occlusion (CTO). Update 2022
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory: relevance and indications - vascular, cardiovascular and thoracic surgery]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for melanoma treatment in adults]
2022     National Institute for Health and Care Excellence (NICE) Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable. NICE technology appraisal guidance 763
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Heart disease in children: can children be helped to cope with their illness through psychological support?]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of non-pharmacological interventions aimed at commerce in controlling the spread of COVID-19]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory: relevance and indications - otolaryngology and oral, maxillofacial and head and neck surgery]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab in non-small-cell lung cancer]
2022     Institute for Clinical and Economic Review (ICER) Unsupported price increase report: unsupported price increases occurring in 2021
2022     National Institute for Health and Care Excellence (NICE) Fremanezumab for preventing migraine. NICE technology appraisal guidance 764
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Social isolation in the elderly: what measures can prevent or counteract social isolation?]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of non-pharmacological interventions aimed at workplaces in controlling the spread of COVID-19]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory: relevance and indications - eye surgery]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for patients with clear-cell renal-cell carcinoma]
2022     Institute for Clinical and Economic Review (ICER) California unsupported price increase report; an evaluation of drug price increases during 2020 in California
2022     National Institute for Health and Care Excellence (NICE) Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE technology appraisal guidance 765
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blood values: do older people benefit from regular determination of vitamin B12 and vitamin D levels in the blood?]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Upper airway stimulation for moderate-to-severe sleep apnoea. Update 2022
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: revision of criteria for the withholding and termination of resuscitation by paramedics in prehospital setting]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Pembrolizumab for advanced or metastatic urothelial carcinoma]
2022     Institute for Clinical and Economic Review (ICER) The next generation of rare disease drug policy: ensuring both innovation and affordability
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma. NICE technology appraisal guidance 766
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Mobility disorders: does the Feldenkrais method help?]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Subcutaneous implantable cardioverter-defibrillator (S-ICD). Update 2022
2022     Austrian Institute for Health Technology Assessment (AIHTA) CAR-T cell therapy: Contrasting the evidence from pivotal trials with the real world evidence (RWE)
2022     National Institute for Health and Care Excellence (NICE) Ponesimod for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 767
2022     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous transvascular implantation of a coronary sinus reducing stent. Update 2022
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: solid organ transplantation – Section 3 - overview of renal and pancreatic transplantation in Québec]
2022     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 768
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Developmental vision disorders: do children and adolescents benefit from active vision training?]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for the treatment of primary membranous nephropathy
2022     Austrian Institute for Health Technology Assessment (AIHTA) Hepatic and portal vein embolisation prior to major hepatectomy
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: chronic obstructive pulmonary disease- detection, diagnosis, optimal use of medications and inhalation devices, and global management]
2022     National Institute for Health and Care Excellence (NICE) Palforzia for treating peanut allergy in children and young people. NICE technology appraisal guidance 769
2022     Austrian Institute for Health Technology Assessment (AIHTA) Microwave ablation for liver tumours
2022     Austrian Institute for Health Technology Assessment (AIHTA) Osteopathy: effectiveness and safety for musculoskeletal pain and overview of training and quality requirements
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer. NICE technology appraisal guidance 770
2022     NIHR Health Technology Assessment programme Exercise to prevent shoulder conditions in patients undergoing breast cancer treatment. The PRevention Of Shoulder Problems Study (PROSPER)
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal pharmacotherapy for transplant ineligible multiple myeloma
2022     Austrian Institute for Health Technology Assessment (AIHTA) His-bundle-pacing for patients requiring a permanent pacemaker or cardiac resynchronisation
2022     National Institute for Health and Care Excellence (NICE) Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 771
2022     Austrian Institute for Health Technology Assessment (AIHTA) Chemosaturation with percutaneous hepatic perfusion for patients with liver cancer
2022     NIHR Health Technology Assessment programme SeHCAT (tauroselcholic [75selenium] acid) for the investigation of bile acid diarrhoea in adults: a systematic review and cost-effectiveness analysis
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies. NICE technology appraisal guidance 772
2022     Austrian Institute for Health Technology Assessment (AIHTA) Lower esophageal sphincter devices for laparoscopic surgery in patients with gastroesophageal reflux disease (GERD)
2022     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 773
2022     Health Technology Wales (HTW) Convalescent plasma therapy for the treatment of COVID-19
2022     Belgian Health Care Knowledge Centre (KCE) Evaluation of Shingrix vaccine against herpes zoster
2022     National Institute for Health and Care Excellence (NICE) Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal). NICE technology appraisal guidance 774
2022     Health Technology Wales (HTW) Extreme hypofractionated radiotherapy (EHFRT) for localised prostate cancer
2022     Austrian Institute for Health Technology Assessment (AIHTA) Child and adolescent mental health care models: a scoping review
2022     National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 775
2022     Austrian Institute for Health Technology Assessment (AIHTA) [Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess individual breast cancer risk, their utility and applicability in a breast cancer screening programme]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: RASopathies Next-generation Sequencing Panel]